Home / Business and Economy / Novartis Beats Q2 Estimates, Reaffirms 2026 Outlook
Novartis Beats Q2 Estimates, Reaffirms 2026 Outlook
21 Jul
Summary
- Novartis reported adjusted earnings of $2.41 per share, exceeding estimates.
- Revenue increased 2.6% to $14.41 billion, surpassing expectations.
- Full-year 2026 outlook reaffirmed despite a 12% drop in free cash flow.
Novartis has announced strong second-quarter results, exceeding financial expectations. The Swiss pharmaceutical company reported adjusted earnings of $2.41 per share, surpassing analyst estimates by $0.26. Revenue for the quarter climbed 2.6% compared to the previous year, reaching $14.41 billion, which was approximately $350 million above Wall Street's predictions.
Despite the positive earnings and revenue figures, the company experienced a 12% decrease in free cash flow, which fell to $5.6 billion. However, Novartis has chosen to reaffirm its financial outlook for the full year 2026. The company continues to expect low-single-digit growth in sales and anticipates a low-single-digit decline in its core operating income for the entire year.
